<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746680</url>
  </required_header>
  <id_info>
    <org_study_id>m308RAP11M</org_study_id>
    <nct_id>NCT01746680</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis</brief_title>
  <acronym>TIARA</acronym>
  <official_title>Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to assess the efficacy and safety of tacrolimus in patients with&#xD;
      active rheumatoid arthritis(RA). EULAR(European League Against Rheumatism) response at week&#xD;
      24 compared to baseline will be evaluated to assess the efficacy of Tacrolimus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase IV, Open labeled, Multi-Center Trial to Assess the Efficacy and Safety of&#xD;
      Tacrolimus(Tacrobell®)in patients with active rheumatoid arthritis(RA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline European League Against Rheumatism(EULAR) response at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Simplified Disease Activity Index(SDAI) at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Korean Health Assessment Questionnaire(KHAQ-20) at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Erythrocyte Sedimentation Rate(ESR) at 16weeks</measure>
    <time_frame>baseline, 16weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Erythrocyte Sedimentation Rate(ESR) at 24weeks</measure>
    <time_frame>baseline, 24eeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline C-Reactive Protein(CRP) at 16weeks</measure>
    <time_frame>baseline, 16weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline C-Reactive Protein(CRP) at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline European League Against Rheumatism(EULAR) response at 16weeks</measure>
    <time_frame>baseline, 16weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus with Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus with Methotrexate</intervention_name>
    <description>Tacrolimus 1 mg for 0~week4, 2mg for week4~week8, 3mg for week8~week24 with MTX ≤20mg/week</description>
    <arm_group_label>Tacrolimus with Methotrexate</arm_group_label>
    <other_name>TacroBell® with MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged ≥20years&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the patient&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test at&#xD;
             the screening visit. Except in the case of surgically sterile or amenorrhea for one&#xD;
             year.&#xD;
&#xD;
          -  Female patients must agree to use adequate contraception measures during the period of&#xD;
             therapy which should be continued for 4 weeks.&#xD;
&#xD;
          -  have RA and meet all of the following criteria; RA occurring ≥ 3months and less than&#xD;
             15 years and diagnosed based on 1987 ACR classification criteria for rheumatoid&#xD;
             arthritis; Active RA patients with MTX and among them who has insufficiency response&#xD;
             to DMARDs as defined DAS28&gt;3.2 in active RA patient. Insufficiency response is defined&#xD;
             despite MTX therapy for &gt; 12 weeks, RA activity≥ more than moderate and confirmable&#xD;
             during 12 weeks, sequence of taking MTX &gt;7.5mg/week for more than 6 weeks; ESR≥28mm/h&#xD;
             or CRP≥1.0mg/dl; Tender Joint Counts must be more than 6 and Swollen Joint Counts must&#xD;
             be more than 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory joint diseases, Systematic inflammatory disease&#xD;
&#xD;
          -  Prosthesis and had an event of infected in it.&#xD;
&#xD;
          -  Medical history of chronic infection, moderate infection or possibly to life&#xD;
             threatening or signs and symptoms of serious infection.&#xD;
&#xD;
          -  Patients have received treatment with a live vaccine from baseline within 8 weeks.&#xD;
&#xD;
          -  HBsAg positive and hepatitis C virus positive patient.&#xD;
&#xD;
          -  Patients have a history of malignancy. (But, carcinoma in situ of the uterine cervix&#xD;
             or basal cell carcinoma have been treated is allowed within 5years)&#xD;
&#xD;
          -  Patients have cardiovascular disease or associated disease which is not controlled.&#xD;
&#xD;
          -  uncontrollable blood sugar(HbA1C ≥8%) or required insulin.&#xD;
&#xD;
          -  Patients with a history of operation on index knee joint which could have influence on&#xD;
             the result and need to have surgery as determined by investigator.&#xD;
&#xD;
          -  At screening, patients have laboratory result as defined by ; white blood cell(WBC) &lt;&#xD;
             3,500/mm3, Absolute Neutrophil Count(ANC) &lt; 1,500/mm3, Hemoglobin &lt; 8.5g/dl, Platelet&#xD;
             count(PLT) &lt; 100,000/mm3, Serum creatinine &gt;1.5*upper limit of normal or 2mg/dl, Total&#xD;
             bilirubin &gt; 2*upper limit of normal, aspartate aminotransferase(AST) &gt; 2*upper limit&#xD;
             of normal, alanine aminotransferase(ALT) &gt; 2*upper limit of normal, alkaline&#xD;
             phosphatase(ALP) &gt; 2*upper limit of normal&#xD;
&#xD;
          -  Patients on any other clinical trial or experimental treatment in the past 8weeks&#xD;
&#xD;
          -  An impossible one who participates in clinical trial by investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung -Jae Hong, phD, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Kyung Hee University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>August 9, 2015</last_update_submitted>
  <last_update_submitted_qc>August 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>Disease Activity Score 28</keyword>
  <keyword>EULAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

